Hormonal
Tirzepatide use is associated with a probable risk of severe rhabdomyolysis and necrotising myopathy, potentially mediated by GLP-1 receptor effects on skeletal muscle glucose metabolism.
If you are taking tirzepatide (or similar GLP-1 drugs) and experience sudden, severe muscle pain, swelling, or weakness—especially if it doesn't match your activity level—seek medical attention immediately. Ask for a Creatine Kinase (CK) blood test. Stopping the medication and receiving IV fluids can resolve the condition, as seen in this case.
In this case, the score was 7, demonstrating a probable association between rhabdomyolysis and the use of tirzepatide... We believe this may be a plausible mechanism for a correlation between use of tirzepatide and other GLP-1 agonists causing rhabdomyolysis.
Why this rating
Based on a single case report with a Naranjo score of 7 (probable), supported by mechanistic literature on GLP-1 receptors in muscle.
Source
Rhabdomyolysis associated with the use of tirzepatide
Kunal Sonavane et al. · European Journal of Case Reports in Internal Medicine · 2025
DOI 10.12890/2025_005392
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →